Immune-boosting combo aims to wipe out rectal cancer before surgery

NCT ID NCT05507112

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests whether adding an immunotherapy drug (tislelizumab) to standard chemoradiation before surgery can improve outcomes for people with locally advanced rectal cancer. About 100 participants will receive the combination treatment, and researchers will measure how many achieve a complete response—meaning no cancer cells remain after treatment. The goal is to see if this approach can shrink or eliminate tumors more effectively than standard therapy alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tislelizumab (PD-1 inhibitor) plus capecitabine and radiation therapy
What this could lead to
If successful, this combination could become a new standard treatment before surgery for locally advanced rectal cancer, potentially increasing the chance of eliminating all cancer cells.
What could go wrong
This is a phase 2 trial with only 100 participants, so results may not apply to everyone. Combining immunotherapy with chemoradiation may increase side effects, and the treatment may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.